{"id":"W2969871358","doi":"","title":"Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.","year":2019,"lang":"en","type":"article","venue":"PubMed","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Medicine; Ixekizumab; Psoriatic arthritis; Dermatology Life Quality Index; Placebo; Quality of life (healthcare); Internal medicine; Psoriasis; Ankylosing spondylitis; Visual analogue scale; Physical therapy; Arthritis; Dermatology; Secukinumab; Alternative medicine; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00179758,0.0003977809,0.0008987281,0.0001269389,0.00009346686,0.0003114506,0.000286386,0.0003605859,0.002662122],"category_scores_gemma":[0.001236516,0.0001669292,0.0009066966,0.0001751337,0.0001673435,0.0003835813,0.000346867,0.0006624474,0.0002850613],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001916028,"about_ca_system_score_gemma":0.0003083569,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002285104,"about_ca_topic_score_gemma":0.0003961599,"domain_scores_codex":[0.9995908,0.0002199753,0.00003033359,0.00004884064,0.00005281426,0.00005715214],"domain_scores_gemma":[0.9993067,0.0001438189,0.000251609,0.00007006741,0.00004567155,0.0001822661],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7076831,0.01802345,0.04139628,0.001748026,0.002103264,0.0002011559,0.0002513562,0.001836336,0.02353613,0.0001174499,0.003178769,0.1999248],"study_design_scores_gemma":[0.285829,0.4720977,0.2294586,0.0001449096,0.001570712,0.0005817496,0.0001453941,0.002264253,0.004653389,0.0001619699,0.003046114,0.00004632252],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997153,0.001266204,0.0001214117,0.00009347644,0.00002384614,0.0001577422,0.000353152,0.00002307338,0.0008079346],"genre_scores_gemma":[0.9977273,0.000361495,0.0003868774,0.0001628408,0.00003854189,0.0001587671,0.0006386808,0.000004307948,0.0005211248],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002662122,"threshold_uncertainty_score":0.009506643,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008959120342113207,"score_gpt":0.2188347810077893,"score_spread":0.2098756606656761,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}